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domain at differentiating adjacent dry eye categories across a range of probability
cut-offs with the following Area Under the Curve (AUC) statistics resulting from
2000 stratified bootstrap replicates for each curve: None versus Mild (AUC0.96,
CI0.90-0.98), Mild versus Moderate (AUC0.74, CI0.66-0.84) and Moderate ver-
sus. Severe (AUC0.82, CI0.74-0.90). CONCLUSIONS: The IDEEL SB domain pro-
vides a simple and effective basis for differentiating categories of patient-reported
dry eye severity.
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OBJECTIVES: A key question when interpreting quality of life data is: which mag-
nitude of change is clinically relevant? To document a minimal important differ-
ence (MID) for the Skindex-29 and Dermatology Life Quality Index (DLQI) in patients
with chronic hand eczema. METHODS: Secondary psychometric analysis was un-
dertaken on data from two cost-of-illness studies in Germany (N310). Patients
completed the Skindex-29 and DLQI. The Skindex-29 is summarised into domains
measuring symptoms, emotions, and functioning, plus a total score. DLQI (10-
items) is assessed as a total score. MID was assessed using statistical methods
including standard error of measurement (SEM) and 1⁄2 standard deviation (1⁄2SD).
Internal consistency was also estimated in order to support estimation of the SEM.
Estimates were benchmarked against existing values. RESULTS: Internal consis-
tency for Skindex dimensions (symptoms 0.834; emotions 0.910; function
0.934) and DLQI (0.835) was confirmed. The MID estimated for DLQI was
(SEM2.04, 1⁄2SD  2.53); and for Skindex-29 was symptoms (SEM8.16, 1⁄2SD 
10.01); emotion (SEM6.80, 1⁄2SD  11.34); function (SEM5.53, 1⁄2SD  10.77) and
total score (SEM4.13, 1⁄2SD  9.51). CONCLUSIONS: The study confirms good in-
ternal consistency properties of the Skindex-29 and DLQI in patients with chronic
hand eczema and demonstrates the MID for this measure. The DLQI MID based on
SEM method is close to a recent report in a Danish study of hand eczema patients
using an anchor-based approach which established the DLQI MID at 2.0 (Hald et al.,
2011). The DLQI MID for other skin diseases has previously been proposed to range
from 2.3 to 5.7 in stable plaque psoriasis (Shikiar et al., 2006) and of 2.24 to 3.10 in
chronic idiopathic urticaria (Shikiar et al., 2005) which is consistent with current
estimates.
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OBJECTIVES: Patients’ ability to perform vision-dependent tasks is essential to
daily function and quality of life. Visual function measures do not typically assess
both corrected and uncorrected function and lack an intermediate visual range
scale. To address these limitations, the current qualitative study identifies the
preliminary content and item pool for a future measure (Functional Assessment of
Visual Tasks - VISTAS). METHODS: Ophthalmology patients (n72) with mild to
severe myopia, hyperopia, presbyopia, astigmatism, cataracts and glaucoma par-
ticipated in a variety of qualitative studies (life event journaling, interviews, on-line
and face-to-face focus groups). The objective of these studies was to identify and
thematically group meaningful visual tasks occurring in the near, intermediate
and distance visual ranges. The journal entries and transcripts were thematically
coded and organized into related domains of life function. RESULTS: Some task
groupings were comprised of activities that occur predominantly within the dis-
tance visual range. These groupings included; mobility (ambulation), driving, lei-
sure and sports, and social functioning. Some task groupings relied more heavily
on the predominantly near and intermediate visual ranges. These groupings in-
cluded; technology use and activities of daily living. Other task groupings were
heterogeneous in terms of visual ranges required for their performance.
CONCLUSIONS: Participants identified a wide variety of distance-specific visual
tasks that impacted the quality of their lives. These included tasks related to their
physical safety as well as to functioning at home and in the workplace. The the-
matic analysis provided a rich body of information with which to design items to
assess important functional dimensions that are made more difficult by visual
impairment. The measurement properties of this pool of candidate items were
evaluated in clinical samples as a part of two larger psychometric validation stud-
ies.
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OBJECTIVES: To psychometrically evaluate the VISTAS item pool and develop four
new distance-specific visual function scales (VISTAS-18). METHODS: Study partic-
ipants (n139) were recruited from those attending an optometry clinic to change
an existing eyeglass prescription. Sampling was balanced across myopic, hyper-
opic, presbyopic, and astigmatic conditions. Four VISTAS-18 Function Scales (Near,
Intermediate, Extended-Intermediate and Distant Function) were identified and
refined using PCA factor analysis with oblique rotation. Lens prescription data and
visual acuity assessments in the near, intermediate and distant ranges were used
to provide concurrent criterion-related validity to the new scales. RESULTS: Partic-
ipants’ mean age was 50.7 years (SD 15.0) and was roughly balanced by gender (f:m
4:3). Astigmatism (97/139), Presbyopia (92/139), Myopia (88/139), Hyperopia (43/139),
and Cataracts (28/139) were the most common causes of poor vision. Factor anal-
ysis revealed three and four-factor solutions that explained over 80% of the vari-
ance in task difficulty. The VISTAS-18 Function Scales were internally consistent
(Cronbach’s Alpha  0.89 - 0.96) with normally distributed uncorrected task diffi-
culty scores and floor effects associated with corrected ratings. Moderate correla-
tions were observed between the uncorrected VISTAS-18 Function Scales scores
and both the logMAR visual acuity (r2 0.41 - 0.63) and temporary lens strength (r2
 0.30 - 0.66). With one exception, the correlations between change in lens strength
and change in VISTAS-18 Function Scale scores were all significant.
CONCLUSIONS: This study provides initial structural and criterion-related validity
for the 4 VISTAS-18 Function Scales. The VISTAS-18 Function Scales responded
linearly across the range of both visual acuity and corrective lens strength in each
distance range. Despite the small numbers of evaluable cases, three of the VISTAS
scales were responsive to relatively minor adjustments in lens strength in the near,
intermediate and distant visual ranges.
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OBJECTIVES: Translation and linguistic validation of patient reported outcomes
(PRO) measures is an essential component of research methodology in preparation
for multinational research studies. The Chronic Urticaria Quality of Life question-
naire (CU-Q2oL) is a disease specific tool developed in Italian to assess chronic
urticaria from the patient’s viewpoint. The objective of this work wasto translate
and linguistically validate the CU-Q2oL from Italian to English for use in the US.
METHODS: The CU-Q2oL was translated into English according to industry stan-
dard methodology. After the translation was completed, five patients completed
the translated questionnaire and participated in a cognitive debriefing interview.
Interviews were conducted using a standardized guide to assess the relevance,
understandability, and appropriateness of the translations. Qualitative analyses
were performed to ensure equivalence and that the content validity of the CU-Q2oL
was maintained for the English version. RESULTS: The study sample consisted of 5
patients diagnosed with chronic idiopathic urticaria (80% male). Mean age of the
patients was 39 years. The sample consisted of English speaking patients in the US.
All CU-Q2oL items were well understood and proved relevant to the patients in this
sample. Of interest, terms such as, “hives”, and “swelling of the eyes” were clearly
understood as intended. CONCLUSIONS: The results indicate that the English ver-
sion of the CU-Q2oL translation is conceptually equivalent to the Italian source
version and easily understood by the target population in the United States. We
consider the translation to be acceptable for PRO assessment in research and clin-
ical practice. Future research could include testing of the questionnaire with pa-
tients in other English-speaking countries to confirm its acceptability beyond the
US.
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OBJECTIVES: Acute otitis media (AOM) is one of the commonest paediatric bacte-
rial infections, often requiring general practitioner/paediatrician consultation and
antibiotic prescription. AOM management guidelines differ between countries. We
aimed to prospectively assess the incidence and economic burden of AOM across
five European countries. METHODS: A large, prospective, observational cohort
study was conducted to investigate AOM incidence in Europe, gathering informa-
tion on clinical symptoms, treatment and quality-of-life. A total of 5882 healthy
children aged 6 years were enrolled from 73 medical practices in Germany, Italy,
Spain, Sweden and the UK. A patient reported outcome (PRO) questionnaire was
distributed to parents to assess costs associated with medically diagnosed AOM.
Assessment included direct medical costs (e.g. medication/physician consulta-
tions/hospitalisations), direct non-medical costs (e.g. transportation/baby-sitting),
and indirect costs (e.g. absence from work/school). RESULTS: Of 1419 AOM epi-
sodes recorded in 1113/5882 children, 91.1% had a questionnaire available. Medi-
cation (any) was taken for 58.8% of episodes, but the proportion varied between
countries (Spain: 14.8%; Germany: 33.2%; Italy: 93.8%; UK: 94.6%; Sweden: 95.7%).
The child missed day-care/school in 48.9% of episodes (median hours missed: 18);
the caregiver missed work in 17.1% of episodes (median hours missed: 16). Hospi-
talisation rates were similar across countries (1.0%). The mean total cost/episode
ranged between €24.16 (Spain) and €306.09 (Sweden). Mean direct medical costs
A508 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
